ICICI Direct: Aurobindo Pharma - Divestiture Of Dietary Supplement Business ‘Natrol’
Capsules are arranged for a photograph in Tokyo, Japan. (Photographer: Kiyoshi Ota/Bloomberg)

ICICI Direct: Aurobindo Pharma - Divestiture Of Dietary Supplement Business ‘Natrol’

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

In an important development, Aurobindo Pharma Ltd. signed a definitive agreement on October 25, 2020, with New Mountain Capital and its affiliate Jarrow Formulas to sell its 'Natrol' business (wholly owned step-down subsidiary) as a going concern with related assets, liabilities, products, brands and employees for a cash consideration of 550 million U.S. dollar (Rs 4048 crore).

Net worth of the company as on March 31, 2020 was at 82.41 million U.S. dollar.

The transaction is expected to be closed by January 2021 subject to customary closing conditions and regulatory approvals.

Click on the attachment to read the full report:

ICICI Direct Aurobindo Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.